Coverage
-
August 02, 2019
Allergan will pay a combined $2.7 million and allow judgment to be entered against it to resolve claims from three of the plaintiffs accusing the company's subsidiary of delaying generic competition for Asacol, according to letters filed in Massachusetts federal court Friday.
26 other articles on this case.
View all »